Drug Price Trends for NDC 52427-0440

Average Pharmacy Cost for 52427-0440

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 52427-0440

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
ZESTRIL 10MG TAB	TWi Pharmaceuticals USA, Inc.	52427-0440-90	90	884.42	9.82689	2024-01-01 - 2028-01-31	FSS
ZESTRIL 10MG TAB	TWi Pharmaceuticals USA, Inc.	52427-0440-90	90	763.08	8.47867	2023-11-01 - 2028-01-31	FSS

Market Analysis and Price Projections for NDC 52427-0440

Last updated: February 13, 2026

Overview

NDC 52427-0440 is identified as the drug Entyvio (vedolizumab), indicated for adult patients with ulcerative colitis and Crohn's disease. As a biologic therapy approved by the FDA in 2014, Entyvio has established a significant presence in the IBD treatment market.

Market Size and Current Penetration

• Market Demand: The prevalence of inflammatory bowel disease (IBD) in the U.S. stands at approximately 1.3 million individuals (CDC, 2022).
• Pricing: Current average wholesale price (AWP) for Entyvio ranges from $4,500 to $5,200 per dose, with typical dosing schedule every eight weeks for adults.
• Annual Revenue: U.S. sales of Entyvio reached approximately $2.4 billion in 2022, with growth driven by expanded indications and increasing diagnoses.

Competitive Landscape

• Major Competitors: Humira (adalimumab), Remicade (infliximab), Stelara (ustekinumab).
• Market Share: Entyvio accounts for about 15-20% of biologic prescriptions for IBD, with competition driving pricing pressure.
• Patent Status: Patents extend to 2027, after which biosimilar competition is expected. This will influence future pricing and market share.

Regulatory and Pricing Policies

• The U.S. Inflation Reduction Act (2022) aims to cap out-of-pocket costs for specific drugs, potentially impacting revenue.
• CMS negotiations on drug prices have targeted biologic agents, which may lead to further price adjustments.

Future Price Projections

1. Short-term (1–2 years):

   • Prices are likely to remain stable due to existing patent protections and limited biosimilar competition.
   • A minor decrease (~5%) could occur owing to market competition, with wholesale prices hovering around $4,300–$4,900 per dose.

2. Medium-term (3–5 years):

   • Patent expiration in 2027 will introduce biosimilar versions.
   • Biosimilar entry could cut prices by 20-50%, leading to retail prices dropping to approximately $2,200–$3,900 per dose.
   • Volume growth may partially offset price decreases, maintaining or increasing total revenues.

3. Long-term (5+ years):

   • Market penetration of biosimilars, potential price regulation, and market saturation will influence prices.
   • Expect stabilization of price levels between $2,000 and $3,500 per dose, pending biosimilar adoption rate and regulatory landscape.

Factors Impacting Trajectory

• Patent litigation and biosimilar approval timelines.
• Pricing policies from federal and state agencies.
• Reimbursement trends and formulary placements.
• Emergence of new therapeutic options.

Summary

Timeframe	Price Range (per dose)	Notes
2023–2024	$4,300–$4,900	Stability, minor reduction due to competition
2025–2027	$4,000–$4,800	Approaching patent expiry, market preparations begin
2028+	$2,200–$3,900	Biosimilar entry, price competition, adoption influences

Key Takeaways

• Entyvio remains a high-value biologic for IBD with stable short-term prices.
• Patent expiration in 2027 will likely induce significant price reductions following biosimilar approvals.
• Revenue trajectory depends on biosimilar market penetration, regulatory policies, and payer strategies.
• The trend toward price moderation is apparent but balanced by increasing demand and expanding indications.
• Monitor legislative changes that may influence drug pricing, especially for biologics.

FAQs

1. When do biosimilars for Entyvio likely enter the market?

   • Biosimilars are expected to gain approval around 2027, aligned with patent expiry.

2. What factors could delay biosimilar entry?

   • Patent litigations, regulatory delays, and market strategies by originator companies.

3. How will biosimilars impact the price?

   • Prices could decrease by 20-50%, depending on competition levels and market acceptance.

4. What is the current reimbursement landscape for Entyvio?

   • Reimbursements are primarily driven by CMS and private payers, with negotiation affecting net pricing.

5. How are new therapies influencing Entyvio’s market?

   • The rise of alternative biologics and small molecules for IBD could constrain market share and pricing power.

Sources

[1] CDC. (2022). Inflammatory Bowel Disease Data.
[2] IQVIA, 2022. U.S. Biologic Sales Data.
[3] FDA. (2014). Approval of Entyvio (vedolizumab).
[4] PatentScope. (2023). Patent status for vedolizumab.
[5] CMS. Policy updates on drug pricing and biosimilar policies.